<DOC>
	<DOCNO>NCT00895297</DOCNO>
	<brief_summary>This phase II efficacy ( indicate capacity beneficial change therapeutic effect ) safety study Dasatinib patient relapse Chronic Myeloid Leukemia ( CML ) follow Stem Cell Transplant ( SCT ) benefit treatment , imatinib therapy . A relapse illness seem get well , cure , come back get bad . A total 50 patient â‰¥18 year age register trial .</brief_summary>
	<brief_title>Efficacy Safety Study Dasatinib Patients With Chronic Myeloid Leukemia</brief_title>
	<detailed_description>Primary Objective : 1 . To assess efficacy Dasatinib therapy chronic accelerate phase BCR-ABL ( + ) ( Ph + Ph - ) CML patient undergo molecular , cytogenetic haematological relapse follow SCT . Secondary Objective ( ) : 1 . To assess impact Dasatinib therapy patient survival relapse post-SCT incidence subsequent need 'rescue ' DLI . 2 . To assess safety Dasatinib clinical context use specific dose regimen Chronic myeloid leukaemia ( CML ) form cancer start cell within bone marrow call haematopoietic stem cell . Stem cell immature cell divide many time eventually produce lymphocyte myeloid cell present blood . They produce bone marrow - spongy tissue find large bone , include pelvis , sternum , limb bone rib . Leukaemia cancer white blood cell . In CML , many myeloid cell ( one main type white blood cell defend body infectious disease ) produce . The myeloid cell release blood immature unable work properly . These immature white blood cell know blast . The immature cell fill bone marrow prevent make blood cell properly . As leukaemia cell mature , ca n't work normal white blood cell , lead increase risk infection . Because bone marrow overcrowd immature white cell also ca n't make enough healthy red cell platelet . CML usually develop slowly , call 'chronic ' myeloid leukaemia . The aim study ass efficacy ( indicate capacity beneficial change therapeutic effect ) leukaemia treatment call dasatinib ( sprycel ) patient relapse Chronic Myeloid Leukaemia ( CML ) follow Stem Cell Transplant ( SCT ) benefit treatment , imatinib therapy . A relapse illness seem get well , cure , come back get bad . Dasatinib work block ( inhibit ) signal within cancer cell cause cell grow divide . The growth cell body control signal switch within cell . When signal growth switch cell trigger grow multiply . People CML abnormal signal protein inside leukaemia cell . This abnormal protein send grow-and-divide signal cell time never switch . Dasatinib find faulty protein lock onto . This prevent protein stimulate cell grow . Dasatinib known signal transduction inhibitor , block 'grow ' signal . The chemical block call tyrosine kinase , dasatinib also know tyrosine kinase inhibitor .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Accelerated Phase</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>1 . Male female patient great equal 18 year age . 2 . Diagnosed BCRABL ( + ) Chronic Myeloid Leukemia ( Philadelphia chromosome positive negative ) 3 . Prior therapy include imatinib 4 . Patients transplant HLAidentical sibling HLAmatched unrelated donor . 5 . Patients transplant first chronic phase accelerate phase . 6 . Patients untreated relapse BCRABL ( + ) CML ( Philadelphia chromosome positive negative ) allogeneic transplantation enter within 6 week first detection relapse . 7 . Molecular , cytogenetic haematological relapse chronic accelerate phase . 8 . Written informed consent . 9 . Absence serious concomitant illness 1 . Patients relapse blast crisis . 2 . Patients transplant blastic transformation CML . 3 . Patients receive therapy relapse withdrawal immunosuppression ( DLI permit ) . 4 . Patients treat investigational agent previous 30 day 5 . Patients previously treat Dasatinib . 6 . Absence write informed consent . 7 . Presence serious concomitant disease . 8 . History significant bleeding disorder unrelated CML . 9 . Pregnancy lactation status positive . 10 . SGOT SGPT 2.5 x upper limit normal range determine laboratory analysis perform . 11 . Total serum bilirubin level 2 x upper limit normal range laboratory analysis perform . 12 . Serum creatinine concentration 1.5 x upper limit normal range laboratory analysis perform . 13 . Concomitant Medications , follow consider exclusion : Category I drug generally accept risk cause Torsades de Points include : ( Patients must discontinue drug 7 day prior start Dasatinib ) : quinidine , procainamide , disopyramide . amiodarone , sotalol , ibutilide , dofetilide . erythromycin , clarithromycin . chlorpromazine , haloperidol , mesoridazine , thioridazine , pimozide , ziprasidone . cisapride , bepridil , droperidol , methadone , arsenic , chloroquine , domperidone , halofantrine , levomethadyl , pentamidine , sparfloxacin , lidoflazine . The concomitant use H2 blocker proton pump inhibitor Dasatinib recommend . The use antacid consider place H2 blocker proton pump inhibitor patient receive Dasatinib therapy . If antacid therapy need , antacid dose administer least 2 hour prior 2 hour dose Dasatinib .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Relapsing allogeneic transplantation</keyword>
	<keyword>Dasatinib</keyword>
	<keyword>Sprycel</keyword>
	<keyword>Philadelphia Chromosomes</keyword>
</DOC>